DSGN 250516 2.50C(DSGN250516C2500) Stock Price Today

US OptionsDetailed Quotes

DSGN250516C2500

Watchlist

2.35
+0.29+14.08%

15min DelayClose May 2 16:00 ET

2.35High2.35Low

Intraday

5D
Daily

News

RBC Capital Maintains Design Therapeutics(DSGN.US) With Hold Rating, Maintains Target Price $5
Moomoo NewsMay 2 14:31 ET · Ratings
Design Therapeutics Says Eye Drops for Fuchs Endothelial Corneal Dystrophy 'Well-Tolerated'
MT NewswiresMay 1 12:29 ET
Design Therapeutics Announces Data From Phase 1 SAD/MAD Trial of DT-168
TipRanksMay 1 08:25 ET
Design Therapeutics Releases Phase 1 Data For DT-168 Supporting Advancement Into Phase 2 Biomarker Trial For Patients With Fuchs Endothelial Corneal Dystrophy
BenzingaMay 1 08:03 ET
Express News | Design Therapeutics Announces Favorable Phase 1 Data for DT-168 Supporting Advancement Into Phase 2 Biomarker Trial for Patients With Fuchs Endothelial Corneal Dystrophy
ReutersMay 1 08:00 ET
Design Therapeutics To Present Update On Progress Of DT-168 Program For FECD At Eyecelerator At Park City 2025 On May 2, 2025
BenzingaApr 21 16:03 ET

Comments

Teddy123

Apr 22 07:30

Design Therapeutics to Present Phase 1 Data for Fuchs Endothelial Corneal Dystrophy Program at Eyecelerator @ Park City 2025

$Design Therapeutics (DSGN.US)$
Revolutionary Eye Drop Could Replace Corneal Transplants: Design Therapeutics Reveals Phase 1 Data for FECD Treatment

Teddy123

Mar 10 19:18

Design Therapeutics Highlights Progress Across Lead GeneTAC® Programs and Reports Fourth Quarter and Full Year 2024 Financial Results

$Design Therapeutics (DSGN.US)$
Design Therapeutics Highlights Progress Across Lead GeneTAC® Programs and Reports Fourth Quarter and Full Year 2024 Financial Results

Wee the Pig

Aug 12, 2024 23:18

Patterns

$Design Therapeutics (DSGN.US)$ head and shoulders pattern forming?

Newbee4

Jul 25, 2024 20:29

Strange Pattern

$Design Therapeutics (DSGN.US)$
@Trytosaveabit

suannai231

Apr 19, 2024 02:09

$Design Therapeutics (DSGN.US)$ Ready